Ikarian Capital, LLC

DALLAS, TX · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$504.1M2026 Q3+ $490.0M options (notional, not included)
Positions172
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.38.2%

Ikarian Capital, LLC reported 172 positions worth $504.1M as of September 30, 2026 (13F filed November 16, 2026). Largest holding: MRNA (7.7%). Biggest move: add BMY ($59.3M).

10 / 172 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 MRNAPutModerna$77.0M notional7.75%400,000———
▸ 2 BMYPutBristol Myers Squibb$61.9M notional6.23%992,500———
▸ 3 KODKodiak Sciences$50.5M5.08%533,113——+6.3%
▸ 4 XBIPutSPDR Series$47.3M notional4.76%300,000———
▸ 5 PRAXCallPraxis Precision Medicines$29.1M notional2.92%99,800———
▸ 6 ABVXAbivax S.A.$28.4M2.86%285,909———
▸ 7 IRONPutDisc Medicine$25.5M notional2.56%389,100———
▸ 8 PCVXVaxcyte$22.8M2.29%400,465——+8.3%
▸ 9 RCUSArcus Biosciences$19.0M1.91%734,559——-32.5%
▸ 10 INCYPutIncyte$18.2M notional1.83%150,000———

Pro Feature

The remaining 162 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Ikarian Capital, LLC hold as of Q3 2026?

Ikarian Capital, LLC reported 172 positions worth $504.1M in its Q3 2026 13F filing. Largest positions: MRNA (7.7%), BMY (6.2%), KOD (5.1%), XBI (4.8%) and PRAX (2.9%).

What did Ikarian Capital, LLC buy in Q3 2026?

New positions: INCY, ACAD, PCVX, SMMT and RAPP (49 in all). Added to: BMY, IRON, PRAX, AMLX and IRON (28 in all).

What did Ikarian Capital, LLC sell in Q3 2026?

Reduced: KOD, ABVX, PRAX, ANIP and BHVN (37 in all). Sold out entirely: ABVX, IONS, IONS, NEWAMSTERDAM PHARMA COMPANY and DAMORA THERAPEUTICS INC (33 in all).

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.